Loading...
XSHE
002349
Market cap856mUSD
Aug 21, Last price  
6.92CNY
1D
-3.89%
1Q
-1.84%
Jan 2017
-31.32%
IPO
105.14%
Name

Jinghua Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XSHE:002349 chart
P/E
26.23
P/S
3.98
EPS
0.26
Div yield, %
1.13%
Shrs. gr., 5y
Rev. gr., 5y
1.28%
Revenues
1.45b
+3.19%
234,869,000259,386,550274,319,820375,502,000665,382,373732,618,192577,753,553780,334,009881,487,1701,120,920,3171,354,705,8801,157,389,4281,281,353,3241,357,868,0131,357,868,0131,573,059,8141,573,059,8131,511,751,3461,402,088,2921,446,864,390
Net income
219m
+3.12%
26,163,00032,799,92942,639,38648,102,00049,223,17735,597,16239,467,84078,081,137165,029,750175,319,964229,665,282-393,617,948110,993,977160,702,159160,702,166212,225,425212,225,428247,697,201212,651,538219,284,778
CFO
347m
+11.47%
22,182,00033,863,00017,129,00057,758,00041,060,00041,445,00077,247,000-54,940,00045,702,000-76,012,000343,802,00075,923,00083,430,000285,382,000328,218,000305,571,000358,390,000291,310,000311,018,000346,685,414
Dividend
May 29, 20260.09 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1957 and headquartered in Nantong, China, Jinghua Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the complete process of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, encompassing their research, development, manufacturing, and distribution. Its essential API offerings include a variety of compounds such as Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine. The company previously operated under the name Nantong Jinghua Pharmaceutical Co., Ltd.
IPO date
Feb 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT